Andrea Zaenglein

Andrea Zaenglein, MD is a Professor holding dual appointments in the Department of Dermatology and Department of Pediatrics, demonstrating expertise spanning both clinical dermatology and pediatric care with emphasis on childhood skin disorders. Her academic profile reflects sustained scholarly productivity since 1992, with 140 research outputs including 87 articles, 16 book chapters, and 12 review articles, alongside an h-index of 26 and over 4,200 Scopus citations.

Dr. Zaenglein's research centers on pediatric dermatological conditions, particularly acne vulgaris management where she has established consensus recommendations and investigated sex-based variations in isotretinoin monitoring. Her work significantly addresses atopic dermatitis in children through recent phase 3 clinical trials of ruxolitinib cream, while also exploring vascular anomalies like infantile hemangiomas with airway involvement and practical wound care challenges such as hypergranulation tissue management. This research portfolio directly contributes to UN Sustainable Development Goal 3 (Good Health and Well-Being) through evidence-based pediatric dermatology advancements.

Current publication trends reveal intensive focus on therapeutic innovations for pediatric inflammatory skin conditions, with 2025 outputs dominated by ruxolitinib clinical trials evaluating efficacy, safety, and quality-of-life impacts in young patients. Parallel work addresses critical clinical decision points including parental treatment refusal in airway hemangiomas and sex-specific laboratory monitoring protocols, reflecting her commitment to translating research into practical clinical guidelines for complex pediatric dermatology scenarios.